JP2003506071A - アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法 - Google Patents

アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法

Info

Publication number
JP2003506071A
JP2003506071A JP2001515696A JP2001515696A JP2003506071A JP 2003506071 A JP2003506071 A JP 2003506071A JP 2001515696 A JP2001515696 A JP 2001515696A JP 2001515696 A JP2001515696 A JP 2001515696A JP 2003506071 A JP2003506071 A JP 2003506071A
Authority
JP
Japan
Prior art keywords
bad
seq
fragment
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2001515696A
Other languages
English (en)
Japanese (ja)
Inventor
キシアオ−メイ ズー，
Original Assignee
アポプトシス テクノロジー，アイエヌシー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アポプトシス テクノロジー，アイエヌシー． filed Critical アポプトシス テクノロジー，アイエヌシー．
Publication of JP2003506071A publication Critical patent/JP2003506071A/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
JP2001515696A 1999-05-28 2000-05-30 アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法 Withdrawn JP2003506071A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13678399P 1999-05-28 1999-05-28
US60/136,783 1999-05-28
PCT/US2000/011864 WO2001010888A1 (fr) 1999-05-28 2000-05-30 Composes et methodes de regulation de l'apoptose, et methodes d'elaboration et de criblage de composes regulateurs de l'apoptose

Publications (1)

Publication Number Publication Date
JP2003506071A true JP2003506071A (ja) 2003-02-18

Family

ID=22474341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001515696A Withdrawn JP2003506071A (ja) 1999-05-28 2000-05-30 アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法

Country Status (5)

Country Link
EP (1) EP1181306A4 (fr)
JP (1) JP2003506071A (fr)
AU (1) AU765983B2 (fr)
CA (1) CA2373814A1 (fr)
WO (1) WO2001010888A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
US8183339B1 (en) 1999-10-12 2012-05-22 Xigen S.A. Cell-permeable peptide inhibitors of the JNK signal transduction pathway
EP1273654A1 (fr) * 2001-07-05 2003-01-08 Schering Aktiengesellschaft BAD comme substrat pour PPC2
JP4142356B2 (ja) 2001-07-05 2008-09-03 オイクロ ヨーロピアン コントラクト リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト Ｐｐ２ｃの基質
JPWO2003018058A1 (ja) * 2001-08-22 2004-12-09 横田　充弘 心筋細胞のアポトーシス抑制剤
WO2003042239A1 (fr) * 2001-11-12 2003-05-22 Stichting Sanquin Bloedvoorziening Peptides inhibant la signalisation des gtpases de type ras
ES2262765T3 (es) * 2002-03-07 2006-12-01 Institut Pasteur Metodos para tamizar compuestos que modulan apoptosis, compuestos identificados por dichos metodos y uso de dichos compuestos como agentes terapeuticos.
WO2003082322A1 (fr) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. Méthode de modulation d'activité cellulaire
JP2004018524A (ja) * 2002-06-13 2004-01-22 Eucro European Contract Research Gmbh & Co Kg 動脈硬化症を処置するための方法
EP1661912A1 (fr) * 2004-11-29 2006-05-31 Xigen S.A. Protéine de fusion comprenant un domaine BH3 d'une protéine BH3-only
US8080517B2 (en) 2005-09-12 2011-12-20 Xigen Sa Cell-permeable peptide inhibitors of the JNK signal transduction pathway
WO2007031098A1 (fr) 2005-09-12 2007-03-22 Xigen S.A. Inhibiteurs peptidiques permeables aux cellules de la voie de transduction de signal jnk
WO2007035494A2 (fr) * 2005-09-16 2007-03-29 The Regents Of The University Of California Induction de l'expression de puma permettant de reduire l'inflammation articulaire dans le traitement de l'arthrite
AU2008229648A1 (en) * 2007-03-20 2008-09-25 The Walter And Eliza Hall Institute Of Medical Research Method of screening
WO2009143865A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques des voies de traduction du signal jnk perméables aux cellules pour le traitement de diverses maladies
WO2009143864A1 (fr) 2008-05-30 2009-12-03 Xigen S.A. Utilisation d'inhibiteurs peptidiques perméables aux cellules de la voie de transduction du signal jnk pour le traitement de maladies digestives inflammatoires chroniques ou non chroniques
WO2010072228A1 (fr) 2008-12-22 2010-07-01 Xigen S.A. Nouvelles constructions transporteuses et molécules conjuguées cargo/transporteuses
WO2011160653A1 (fr) 2010-06-21 2011-12-29 Xigen S.A. Nouvelles molécules inhibant jnk
JP5857056B2 (ja) 2010-10-14 2016-02-10 ザイジェン インフラメーション エルティーディー 慢性又は非慢性の炎症性眼疾患を治療するためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の使用
WO2013091670A1 (fr) 2011-12-21 2013-06-27 Xigen S.A. Nouvelles molécules inhibitrices de jnk pour le traitement de diverses maladies
WO2015197097A1 (fr) 2014-06-26 2015-12-30 Xigen Inflammation Ltd. Nouvelle utilisation pour des molécules inhibitrices de la jnk, pour le traitement de diverses maladies
US10624948B2 (en) 2013-06-26 2020-04-21 Xigen Inflammation Ltd. Use of cell-permeable peptide inhibitors of the JNK signal transduction pathway for the treatment of various diseases
WO2014206427A1 (fr) 2013-06-26 2014-12-31 Xigen Inflammation Ltd. Nouvelle utilisation d'inhibiteurs de peptides à perméabilité cellulaire dans la voie de transduction du signal jnk pour le traitement de diverses maladies

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965703A (en) * 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use

Also Published As

Publication number Publication date
AU765983B2 (en) 2003-10-09
CA2373814A1 (fr) 2001-02-15
EP1181306A4 (fr) 2003-06-18
EP1181306A1 (fr) 2002-02-27
WO2001010888A1 (fr) 2001-02-15
AU5125300A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
JP2003506071A (ja) アポトーシスを制御する化合物および方法ならびにアポトーシスを制御する化合物を製造およびスクリーニングする方法
US5856445A (en) Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
AU722622B2 (en) BH3 interacting domain death agonist
WO1998009980A9 (fr) Agoniste de mort a domaine d'interaction bh3
US7709600B2 (en) Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto
US7982002B2 (en) Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto
JP2005040137A (ja) Ｊｎｋを標的化することによりプログラム細胞死またはアポトーシスをブロックする新規な因子の同定
EP1212362A2 (fr) Nouvelles proteines card participant a la regulation de l'apoptose
WO1998009643A1 (fr) Modulation de l'apoptoste par phophorylation de la serine du regulateur de mort cellulaire associe a bcl-xl/bcl-2
US7193044B1 (en) Compounds and methods for regulating apoptosis, and methods of making and screening for compounds that regulate apoptosis
NEILL et al. Binding of the merlin-I product of the neurofibromatosis type 2 tumour suppressor gene to a novel site in β-fodrin is regulated by association between merlin domains
US8404806B2 (en) Isolated BRCA1 peptides and method of use
US7579161B2 (en) Assay methods for suppressor of fused modulation of hedgehog signaling
CA2362963C (fr) Suppresseur humain de proteine fusionnee
US7041783B2 (en) Survivin-binding proteins, encoding nucleic acids, and methods of use
WO2008034133A2 (fr) Effet du tula sur la production de lentivirus pseudotypés à base de hiv-1
ZA200106937B (en) Human suppressor of fused.

Legal Events

Date Code Title Description
A300 Withdrawal of application because of no request for examination

Free format text: JAPANESE INTERMEDIATE CODE: A300

Effective date: 20070807